CGH :老年评估缺陷与炎症性肠病老年患者的疾病活动性和疾病负担相关性研究

2022-06-13 医路坦克 MedSci原创

老年患者中炎症性肠病(IBD)的发病率和流行率正在上升,本文旨在对患有炎症性肠病(IBD)的老年患者进行老年评估,以评估哪些IBD特征与老年评估中的缺陷相关,以及缺陷对疾病负担的影响。

炎症性肠病(IBD),包括克罗恩病(CD)和溃疡性结肠炎(UC),是一种慢性免疫介导的疾病。老年患者中IBD的发病率和流行率正在上升;据估计,在未来十年中,老年IBD患者将占所有炎症性肠病患者的三分之一以上。由于与年轻患者相比,老年患者在身体、功能、精神和社会能力方面存在异质性,因此老年患者构成了一个具有挑战性的患者群体。这些老年领域通过老年评估进行衡量,然后整合到整体虚弱水平中。对老年患者的老年损伤的研究越来越受到关注。例如,在老年癌症患者中,虚弱与治疗期间和治疗后的功能不良和高症状负担有关,与疾病相关因素无关。此外,在患有肝硬化的成年患者中,身体虚弱与等候名单死亡率有关,与腹水或肝性脑病无关。最近,Kochar等人发现虚弱与接受免疫抑制药物治疗的IBD成年患者的感染有关,并与所有炎症性肠病患者的死亡率有关。然而,到目前为止, 目前尚无证据表明老年IBD患者老年评估缺陷的普遍性,也没有前瞻性研究表明其对不良健康结果或生活质量的影响。

我们旨在对患有炎症性肠病(IBD)的老年患者进行老年评估,以评估哪些IBD特征与老年评估中的缺陷相关,以及缺陷对疾病负担(健康相关生活质量)的影响。

一项前瞻性多中心队列研究,包括405名连续门诊的65岁以上IBD患者。评估了躯体领域(共病、多药症、营养不良)、日常生活(工具性)活动损伤、身体能力(握力、步态速度)、精神领域(抑郁症状、认知障碍)和社会领域(生活伴侣)。老年评估中的缺陷被定义为2个异常领域;2-3个中度赤字和4-5个严重赤字。评估了临床(Harvey Bradshaw指数> 4/部分Mayo评分> 2)和生化(C反应蛋白10 mg/L和/或粪便钙卫蛋白250 mg/g)疾病活动和疾病负担(简短炎症性肠病问卷)。

躯体领域(51.6%)和日常生活活动能力(43.0%)最常受损。共有160名(39.5%)患者在他们的老年评估中有中度缺陷;重度32例(7.9%)。与缺陷相关的临床和生化疾病活动(临床:调整比值比,2.191;95%置信区间,1.284–3.743;p[. 004;生化:调整后的比值比,3.358;95%置信区间,1.936–5.825;P < .001)。老年评估的缺陷与较低的健康相关生活质量独立相关。

老年评估缺陷在老年IBD患者中非常普遍。患有活动性疾病的患者更容易出现赤字,赤字与较低的健康相关生活质量相关,表明疾病负担较高。验证虚弱和老年评估对结果的影响的前瞻性数据保证了进一步改善治疗策略。

文献来源:Asscher VER,  Waars SN,  van der Meulen-de Jong AE, Deficits in Geriatric Assessment Associate With Disease Activity and Burden in Older Patients With Inflammatory Bowel Disease.Clin Gastroenterol Hepatol 2022 May;20(5)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690874, encodeId=3ac716908e4dc, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jun 09 03:21:23 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058383, encodeId=62e5205838342, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Apr 01 05:21:23 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724052, encodeId=b5f21e24052d7, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Thu Nov 03 01:21:23 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756125, encodeId=e84c1e56125c6, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Mon Jun 27 23:21:23 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838074, encodeId=5add18380e47c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jan 30 15:21:23 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333638, encodeId=709113336386a, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547555, encodeId=cd88154e55570, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690874, encodeId=3ac716908e4dc, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jun 09 03:21:23 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058383, encodeId=62e5205838342, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Apr 01 05:21:23 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724052, encodeId=b5f21e24052d7, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Thu Nov 03 01:21:23 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756125, encodeId=e84c1e56125c6, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Mon Jun 27 23:21:23 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838074, encodeId=5add18380e47c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jan 30 15:21:23 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333638, encodeId=709113336386a, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547555, encodeId=cd88154e55570, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2023-04-01 chendoc242
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690874, encodeId=3ac716908e4dc, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jun 09 03:21:23 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058383, encodeId=62e5205838342, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Apr 01 05:21:23 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724052, encodeId=b5f21e24052d7, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Thu Nov 03 01:21:23 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756125, encodeId=e84c1e56125c6, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Mon Jun 27 23:21:23 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838074, encodeId=5add18380e47c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jan 30 15:21:23 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333638, encodeId=709113336386a, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547555, encodeId=cd88154e55570, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690874, encodeId=3ac716908e4dc, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jun 09 03:21:23 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058383, encodeId=62e5205838342, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Apr 01 05:21:23 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724052, encodeId=b5f21e24052d7, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Thu Nov 03 01:21:23 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756125, encodeId=e84c1e56125c6, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Mon Jun 27 23:21:23 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838074, encodeId=5add18380e47c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jan 30 15:21:23 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333638, encodeId=709113336386a, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547555, encodeId=cd88154e55570, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690874, encodeId=3ac716908e4dc, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jun 09 03:21:23 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058383, encodeId=62e5205838342, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Apr 01 05:21:23 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724052, encodeId=b5f21e24052d7, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Thu Nov 03 01:21:23 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756125, encodeId=e84c1e56125c6, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Mon Jun 27 23:21:23 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838074, encodeId=5add18380e47c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jan 30 15:21:23 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333638, encodeId=709113336386a, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547555, encodeId=cd88154e55570, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1690874, encodeId=3ac716908e4dc, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jun 09 03:21:23 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058383, encodeId=62e5205838342, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Apr 01 05:21:23 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724052, encodeId=b5f21e24052d7, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Thu Nov 03 01:21:23 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756125, encodeId=e84c1e56125c6, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Mon Jun 27 23:21:23 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838074, encodeId=5add18380e47c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jan 30 15:21:23 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333638, encodeId=709113336386a, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547555, encodeId=cd88154e55570, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1690874, encodeId=3ac716908e4dc, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jun 09 03:21:23 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058383, encodeId=62e5205838342, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Apr 01 05:21:23 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724052, encodeId=b5f21e24052d7, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Thu Nov 03 01:21:23 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756125, encodeId=e84c1e56125c6, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Mon Jun 27 23:21:23 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838074, encodeId=5add18380e47c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jan 30 15:21:23 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333638, encodeId=709113336386a, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547555, encodeId=cd88154e55570, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Tue May 31 02:21:23 CST 2022, time=2022-05-31, status=1, ipAttribution=)]

相关资讯

JCC: 炎症性肠病与脊柱关节炎之间的关联

强直性脊柱炎(英文简称AS)是一种血清反映阳性,病因不太明了的常见中枢关节疑难疾病,但与遗传性因素和感染因子等有关,强直性脊椎炎多发于中青年,15岁—40岁之间患此病者占79%。

JGH:长期使用硫嘌呤不会增加炎症性肠病患者淋巴瘤和非黑色素瘤皮肤癌的风险

炎症性肠病广义的是包括各种的肠道炎性疾病,一般来说是累及回肠、直肠、结肠这些的都可以叫炎性肠病,它的表现一般都是腹泻、腹痛。

AP&T: 炎症性肠病患者使用抗抑郁药物的几率高于一般人群

抑郁症是现在最常见的一种心理疾病,以连续且长期的心情低落为主要的临床特征,是现代人心理疾病最重要的类型。

IBD: 血清富含亮氨酸的Alpha-2糖蛋白在评估克罗恩病内镜疾病活动中的准确性

炎性肠病(IBD),如克罗恩氏病(CD)和溃疡性结肠炎(UC)的病因仍是未知的,并且这些基本的患病率正在逐渐增加。

IBD: 牙周炎对炎症性肠病活动的影响

牙周炎的重要致病因素是微生物菌群失调及其引发的慢性炎症和组织破坏,其中嗜中性粒细胞和巨噬 细胞可能发挥重要作用。

Clin Trans Gastroenterology: microRNA的组成不同可以作为溃疡性结肠炎与结肠肿瘤的鉴别标志物

变是炎症性肠病(IBD)最 严重的并发症之一.IBD相关的肿瘤与散发性肿瘤的临床特点并不完全相同.重视相关危险因素,凭借内镜新技术,IBD相关肿瘤的早期诊断将有助于提高患者的生存期。